Cipla Limited (LUX: CIPLA)

Luxembourg flag Luxembourg · Delayed Price · Currency is EUR · Price in USD
16.20
-0.20 (-1.22%)
At close: Jan 27, 2025
-1.82%
Market Cap 12.71B
Revenue (ttm) 3.03B
Net Income (ttm) 563.17M
Shares Out n/a
EPS (ttm) 0.70
PE Ratio 22.57
Forward PE n/a
Dividend n/a
Ex-Dividend Date Aug 1, 2024
Volume n/a
Average Volume n/a
Open n/a
Previous Close 16.40
Day's Range n/a
52-Week Range n/a
Beta n/a
RSI 31.80
Earnings Date Jan 28, 2025

About Cipla

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormaliti... [Read more]

Industry Pharmaceutical Preparations
Founded 1935
Employees 27,764
Stock Exchange Luxembourg Stock Exchange
Ticker Symbol CIPLA
Full Company Profile

Financial Performance

In 2023, Cipla's revenue was 255.37 billion, an increase of 13.20% compared to the previous year's 225.59 billion. Earnings were 41.22 billion, an increase of 47.10%.

Financial numbers in INR Financial Statements

News

There is no news available yet.